COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 457.0 | 9 | 0008-0118 | 570.68 | 118.15 | 240 | 60.53 | 0.823 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 424.2 | 9 | 0009-0145 | 347.01 | 145.15 | 199 | 53.11 | 0.886 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 659.1 | 9 | 0010-0148 | 694.70 | 149.05 | 194 | 59.36 | 0.692 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 424.4 | 9 | 0011-0150 | 125.25 | 150.20 | 225 | 59.46 | 0.800 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 418.7 | 9 | 0012-0157 | 97.26 | 157.47 | 266 | 59.11 | 0.957 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 371.9 | 9 | 0013-0183 | 323.97 | 183.54 | 246 | 61.60 | 0.815 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 454.3 | 9 | 0014-0194 | 251.35 | 194.46 | 224 | 57.36 | 0.856 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 385.6 | 9 | 0015-0206 | 858.14 | 205.90 | 261 | 62.18 | 0.848 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 396.1 | 9 | 0016-0210 | 14.17 | 209.59 | 216 | 55.60 | 0.878 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 492.8 | 9 | 0017-0211 | 377.37 | 210.79 | 172 | 54.04 | 0.740 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 503.9 | 9 | 0018-0224 | 388.18 | 223.96 | 199 | 56.53 | 0.783 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 447.3 | 9 | 0019-0235 | 80.57 | 235.54 | 201 | 56.18 | 0.800 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 582.0 | 9 | 0020-0244 | 687.08 | 243.72 | 274 | 63.36 | 0.858 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 3046.9 | 9 | 0021-0246 | 299.45 | 245.54 | 343 | 72.43 | 0.822 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 465.9 | 9 | 0022-0255 | 445.90 | 255.26 | 242 | 57.94 | 0.906 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 606.4 | 9 | 0023-0268 | 478.14 | 267.59 | 245 | 58.77 | 0.891 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 406.4 | 9 | 0024-0306 | 621.04 | 306.21 | 306 | 65.60 | 0.894 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 364.5 | 9 | 0025-0336 | 263.52 | 336.65 | 255 | 77.50 | 0.534 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 325.5 | 9 | 0026-0338 | 565.15 | 337.78 | 294 | 65.60 | 0.859 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 637.4 | 9 | 0027-0352 | 423.01 | 352.32 | 230 | 57.36 | 0.879 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 610.9 | 9 | 0028-0359 | 647.64 | 359.30 | 201 | 52.04 | 0.933 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 324.7 | 9 | 0029-0366 | 121.04 | 366.56 | 347 | 72.08 | 0.839 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 398.6 | 9 | 0030-0371 | 599.07 | 371.81 | 274 | 62.77 | 0.874 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 346.6 | 9 | 0031-0392 | 112.90 | 392.27 | 302 | 70.18 | 0.770 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 515.3 | 9 | 0032-0394 | 544.89 | 393.62 | 265 | 87.64 | 0.434 |